Discover the game-changing VS Code extensions that every Python developer needs. Boost productivity, catch errors in real-time, and make coding more intuitive with these must-have tools.

Myeloma Trial Results Spark Talk of 'Potential Cure' — One-third of patients alive and progression-free 5 or more years after a single infusion ...

Treatment for multiple myeloma has evolved significantly, with long-term survival increasingly within reach for many patients. Achieving optimal outcomes requires not only addressing symptoms but ...

Pfizer Inc. is currently conducting a Phase 3 clinical study titled ‘MagnetisMM-32’ to evaluate the effectiveness of the drug elranatamab in treating relapsed or refractory multiple myeloma ...

Academy Sports and Outdoors is growing margins, attracting high-income shoppers, and boosting FCF with buybacks and expansion. See why ASO stock is a buy.

Chart Industries and Flowserve merge to create a $19B industrial-tech giant. Discover strategic synergies, industry scale, and financial insights.

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death.

Background: Minimal residual disease (MRD) has been recently accepted by the Food and Drug Administration (FDA) as an endpoint for accelerated approval in Multiple Myeloma. However, emerging data from ...

While it's common for business owners to focus on perfecting products or securing more funding, the real game changer is leadership.

New studies highlight potential of artificial intelligence to improve outcomes for patients with heart failure and cardiac arrest ...

Almost everyone interviewed during jury selection on Tuesday had heard of the case in some capacity. Many people had seen the video and read news articles about it.

New 4D Brain Map reveals potential early warning signs of multiple sclerosis Key players underlying disease onset and repair Date: March 2, 2025 Source: NIH/National Institute of Neurological ...